PF-02413873

• Description:

  PF-02413873 (PF-2413873) is a potent selective, fully competitive and orally active nonsteroidal progesterone receptor (PR) antagonist, with a Ki of 2.6 nM. PF-02413873 can block progesterone binding and PR nuclear translocation, and inhibit endometrial growth in vivo[1][2].

• Product Name Alternative:

  PF-2413873

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319

• Target:

  Progesterone Receptor

• Type:

  Reference compound

• Related Pathways:

  Vitamin D Related/Nuclear Receptor

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Endocrinology

• Assay Protocol:

  https://www.medchemexpress.com/pf-02413873.html

• Purity:

  99.88

• Solubility:

  DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles:

  N#CC1=C(C)C=C(OC2=C(C)N(CS(=O)(C)=O)N=C2C3CC3)C=C1C

• Molecular Formula:

  C18H21N3O3S

• Molecular Weight:

  359.44

• Precautions:

  H302, H315, H319

• References & Citations:

  [1]Howe DC, et, al. The translational efficacy of a nonsteroidal progesterone receptor antagonist, 4-[3-cyclopropyl-1- (mesylmethyl) -5-methyl-1H-pyrazol-4-yl]oxy, -2,6-dimethylbenzonitrile (PF-02413873), on endometrial growth in macaque and human. J Pharmacol Exp Ther. 2011 Nov;339 (2) :642-53.|[2]Bungay PJ, et, al. Preclinical and clinical pharmacokinetics of PF-02413873, a nonsteroidal progesterone receptor antagonist. Drug Metab Dispos. 2011 Aug;39 (8) :1396-405.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 1

• CAS Number:

  [936345-35-6]